Beam Therapeutics Inc. (NASDAQ:BEAM) is a top innovative stock according to Wall Street analysts, with a Buy rating and $80 price target from H.C. Wainwright. The company recently secured FDA agreement for an expedited approval process for BEAM-302 therapy in alpha-1 antitrypsin deficiency (AATD).

In its Phase 1/2 trial, Beam Therapeutics Inc. (NASDAQ:BEAM) plans to enroll 50 more patients for its BEAM-302 therapy by the first quarter of 2026. The company ended 2025 with $1.25 billion in cash, extending its financial runway beyond 2029 for crucial development and commercialization.

Specializing in precision genetic medicines, Beam Therapeutics Inc. (NASDAQ:BEAM) utilizes base-editing technology for products like BEAM-101 and BEAM-302. The company is well-funded and progressing towards key milestones and product launches.

While BEAM shows promise, other AI stocks may offer greater upside potential and lower risks. For those seeking undervalued AI stocks, a free report on the best short-term AI stock is available. This article is published by Insider Monkey.

Read more at Yahoo Finance: H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval